| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 01/31/2002 | WO2001070668A3 Amines substituted with a dihydronaphthalenyl, crhomenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
| 01/31/2002 | WO2001062775A3 Novel antiarrhythmic peptides |
| 01/31/2002 | WO2001062341A3 Combination product for the treatment of obesity |
| 01/31/2002 | WO2001060832A3 Pluraflavins and derivatives thereof, process for their preparation and use thereof |
| 01/31/2002 | WO2001044284A3 Chimeric natriuretic peptides |
| 01/31/2002 | WO2001038503A3 Novel human protein kinases and protein kinase-like enzymes |
| 01/31/2002 | WO2001036605A3 2786, a human aminopeptidase |
| 01/31/2002 | WO2001008634A3 Polynucleotide encoding a human serine protease |
| 01/31/2002 | WO2000059941A9 Purposeful movement of human migratory cells away from an agent source |
| 01/31/2002 | WO2000047219A3 Methods and reagents for treating glucose metabolic disorders |
| 01/31/2002 | US20020013358 Indole derivatives |
| 01/31/2002 | US20020013357 Valdecoxib compositions |
| 01/31/2002 | US20020013356 New polycyclic indanylimidazoles with alpha2 adrenergic activity |
| 01/31/2002 | US20020013354 p38 map kinase inhibitors |
| 01/31/2002 | US20020013352 Novel substituted diamine derivatives useful as motilin antagonists |
| 01/31/2002 | US20020013349 Administering drug which opens potassium channel for reducing pain |
| 01/31/2002 | US20020013347 Tri-aryl-substituted-ethane PDE4 inhibitors |
| 01/31/2002 | US20020013339 Nutritional and therapeutic uses of 3-hydroxyalkanoate oligomers |
| 01/31/2002 | US20020013334 HMG-CoA reductase inhibitors and method |
| 01/31/2002 | US20020013278 Using an interleukin-1 beta converting enzyme inhibitor pro-drug to treat apoptosis-, interferon-gamma inducing factor or interferon-gamma inducing diseases; antiinflammatory and -proliferative agents; autoimmune/degenerative disesesdiseases |
| 01/31/2002 | US20020013268 Synergistic effect of a sulfonylurea and/or non-sulfonylurea Kchannel blocker, and a phosphodiesterase 3 type inhibitor |
| 01/31/2002 | US20020013267 Inhibition of neonatal hyperbilirubinemia in breast fed infants |
| 01/31/2002 | US20020013256 Novel inhibitors of formation of advanced glycation endproducts (AGES) |
| 01/31/2002 | US20020012992 Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor |
| 01/31/2002 | US20020012906 Method for kidney disease treatment by drug intervention |
| 01/31/2002 | US20020012733 Compositions for reducing hypercholesterolemia and controlling of postprandial blood glucose and insulin levels |
| 01/31/2002 | US20020012723 Containing sugar to provide freezing and thawing stability; foods, drinks; treatment of anemia |
| 01/31/2002 | US20020012704 Water-insoluble drug particle process |
| 01/31/2002 | US20020012701 Mixture of polyvinyl acetate, polyvinylpyrrolidone, active ingredients, water-soluble polymers or low or high molecular weight lipophilic additives are heated, granulated |
| 01/31/2002 | US20020012666 Administering to animal an egg product wherein the egg product is obtained from an egg-producing animal which has been hyperimmunized with an immunogenic vaccine |
| 01/31/2002 | DE10035513A1 Wirkstoffkombinationen bzw. Addukte aus Cyclodextrinen und mindestens einem Chinon und/oder mindestens einem Hydrochinon und Verwendung solcher Wirkstoffkombinationen in kosmetischen Zubereitungen Active compound combinations or adducts of cyclodextrins and at least one quinone and / or at least one hydroquinone and use of such drug combinations in cosmetic preparations |
| 01/31/2002 | DE10035227A1 Selection and use of lipogenesis inhibitors for the treatment and prevention of obesity |
| 01/31/2002 | CA2797652A1 Multi-component biological transport systems |
| 01/31/2002 | CA2418215A1 Novel fibroblast growth factor (fgf23) and methods for use |
| 01/31/2002 | CA2417134A1 Ho-1 suppressor as a diagnostic and prognostic test for dementing diseases |
| 01/31/2002 | CA2417127A1 Compounds and inhibitors of phospholipases |
| 01/31/2002 | CA2417005A1 Regulators of ppar.delta.(.beta.) and their use in the treatment of obesity and insulin resistance |
| 01/31/2002 | CA2416691A1 Proteases |
| 01/31/2002 | CA2416647A1 Method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity |
| 01/31/2002 | CA2416544A1 Mu-conopeptides |
| 01/31/2002 | CA2416537A1 Calcilytic compounds |
| 01/31/2002 | CA2416414A1 Human kinases |
| 01/31/2002 | CA2415742A1 N-substituted indoles useful in the treatment of diabetes |
| 01/31/2002 | CA2415740A1 Pyrrolidine derivatives as metalloprotease inhibitors |
| 01/31/2002 | CA2415585A1 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission |
| 01/31/2002 | CA2415362A1 Method for treating fibrotic diseases or other indications |
| 01/31/2002 | CA2415077A1 Cell cycle proteins and mitosis-associated molecules |
| 01/31/2002 | CA2415054A1 Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging |
| 01/31/2002 | CA2415046A1 Novel form of (r)-n-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide |
| 01/31/2002 | CA2412626A1 Il-17 molecules and uses thereof |
| 01/31/2002 | CA2411195A1 Aryl sulfonamides as serotonin antagonist for the treatment of obesity |
| 01/31/2002 | CA2411192A1 Combination of serotonin agonist (5ht2) and antagonist (5ht6)as a pharmaceutical formulation |
| 01/31/2002 | CA2410562A1 Colchinol derivatives as angiogenesis inhibitors |
| 01/31/2002 | CA2354331A1 Composition and method for treatment of gastrointestinal disorders, hyperlipidemia, autoimmune diseases and obesity |
| 01/30/2002 | EP1176208A1 Koji molds and use thereof for preparing cholesterol-lowering products |
| 01/30/2002 | EP1176149A1 Novel gymnemic acid derivatives, process for the preparation thereof and use thereof as medicine |
| 01/30/2002 | EP1176134A1 Ligands of nuclear receptors ppar's |
| 01/30/2002 | EP1175904A2 Method for inhibiting bone resorption |
| 01/30/2002 | EP1175903A2 Method for inhibiting bone resorption |
| 01/30/2002 | EP1175900A2 Use of growth hormone secretagogues for improvement of fucnctional health status |
| 01/30/2002 | EP1175504A1 Dna encoding the human vanilloid receptor vr1 |
| 01/30/2002 | EP1175503A1 49 human secreted proteins |
| 01/30/2002 | EP1175498A2 Nucleic acid-antibody conjugate for delivering a foreign nucleic acid in cells |
| 01/30/2002 | EP1175487A2 Pancreatic progenitor cells, methods and uses related thereto |
| 01/30/2002 | EP1175446A1 Human antibodies that bind human il-12 and methods for producing |
| 01/30/2002 | EP1175444A1 Amino-terminal modified parathyroid hormone (pth) analogs |
| 01/30/2002 | EP1175443A1 Modified exendins and exendin agonists |
| 01/30/2002 | EP1175433A1 Androgen glycosides and androgenic activity thereof |
| 01/30/2002 | EP1175421A1 9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS |
| 01/30/2002 | EP1175420A2 Process for preparing n6-substituted deaza-adenosine derivatives |
| 01/30/2002 | EP1175418A2 Thiazolidinedione derivative and its use as antidiabetic |
| 01/30/2002 | EP1175417A1 Substituted benzolactam compounds |
| 01/30/2002 | EP1175412A1 Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents |
| 01/30/2002 | EP1175409A1 Pyrimidinones derivatives for the treatment of atherosclerosis |
| 01/30/2002 | EP1175408A1 Pyrimidinone compounds |
| 01/30/2002 | EP1175406A1 Imidazoline derivatives as alpha-1a adrenoceptor ligands |
| 01/30/2002 | EP1175390A1 Disodium salts, monohydrates, and ethanol solvates |
| 01/30/2002 | EP1175383A1 Glucocorticoid receptor modulators |
| 01/30/2002 | EP1175246A1 UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY HMG-CoA REDUCTASE INHIBITORS |
| 01/30/2002 | EP1175214A2 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 01/30/2002 | EP1175213A2 Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| 01/30/2002 | EP1175205A2 Inhibitors of crystallization in a solid dispersion |
| 01/30/2002 | EP1175157A1 Low molecular weight polymannuronate |
| 01/30/2002 | EP1021442B1 8-azabicyclo 3.2.1] octane-3-methanamine derivatives as ligands of d2 and d3 dopamine and 5ht1a and 5ht2 serotonin receptors |
| 01/30/2002 | EP0900225B1 Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents |
| 01/30/2002 | CN1333773A Process for preparing N6-substituted deaza-adenosine derivatives |
| 01/30/2002 | CN1333767A Aromatic heterocyclic compounds as antiinflammatory agent |
| 01/30/2002 | CN1333762A Novel 2-(N-cyanoimino) thiazolidin-4-one derivatives |
| 01/30/2002 | CN1333756A Crystalline bis [(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl (methylsulfonyl)amino] pyrimidin-5-yl](3R,5S-3,5-dihydroxyhept-6-enoic acid] calcium salt |
| 01/30/2002 | CN1333754A Benzoheterocycles and their use as MEK inhibitors |
| 01/30/2002 | CN1333747A ((Aminoiminomethyl) amino) alkanecarboxamides and their applications in therapy |
| 01/30/2002 | CN1333684A Use of 5HT3 receptor antagouists for the treatment of chronic fatigue syndrome |
| 01/30/2002 | CN1333683A Pharmaceutical composition for modified release insulin sensitiser |
| 01/30/2002 | CN1333681A Use of tertbutylhydroquinone for lowering blood cholesterol and/or blood tribly cerides |
| 01/30/2002 | CN1333372A Process for preparing potide zinc easy absorbed in human body |
| 01/30/2002 | CN1333047A Yunnan pine nut extract and preparation process and use thereof |
| 01/30/2002 | CN1333044A Wasting-thirst hypoglycemic preparation |
| 01/30/2002 | CN1333041A Health care tea and production method thereof |
| 01/30/2002 | CN1333037A Traditional Chinese medicine ingredient and prescription for treating diabetes |
| 01/30/2002 | CN1333032A 复方绞股蓝茶 Compound Gynostemma tea |